HIV integrase mutations can influence how the virus responds to antiretroviral medications, particularly integrase strand transfer inhibitors. Changes in the integrase enzyme may reduce drug sensitivity, allowing HIV to continue replicating despite treatment. Understanding these mutations helps explain treatment resistance, viral rebound, and the importance of resistance testing. This article explores common integrase mutations.
Integrase inhibitors are an important class of antiretroviral medications. These drugs prevent HIV integrase from inserting viral DNA into the host cell's genetic material. Examples include dolutegravir, bictegravir, raltegravir, elvitegravir, and cabotegravir.
However, HIV can develop genetic changes that affect the structure or function of integrase. These changes, known as integrase mutations, may reduce the effectiveness of certain medications. Their impact depends on the specific mutation, the combination of mutations, and the medication being used.
HIV replicates rapidly and produces genetic variations during replication. When antiretroviral medication does not fully suppress viral activity, resistant variants may gain a survival advantage.
Several factors can contribute to the development of integrase inhibitor resistance:
Incomplete viral suppression: Ongoing viral replication can allow resistant variants to emerge.
Treatment interruptions: Repeated interruptions may create conditions that support resistance development.
Pre-existing mutations: Some viral populations may already contain genetic variations affecting drug sensitivity.
Drug exposure: Inadequate medication exposure can reduce treatment effectiveness.
Multiple mutations: Additional mutations may increase resistance or compensate for reduced viral fitness.
Researchers have identified several mutations associated with resistance to integrase strand transfer inhibitors. Important examples include:
N155H: Associated with resistance to raltegravir and elvitegravir.
Q148H, Q148K, and Q148R: These mutations can significantly reduce susceptibility, particularly when accompanied by additional mutations.
Y143C, Y143H, and Y143R: Commonly associated with raltegravir resistance.
G140S and E138K: These mutations can contribute to resistance when combined with Q148 pathway mutations.
R263K: Associated with reduced susceptibility to dolutegravir and certain other integrase inhibitors.
Not every mutation produces the same resistance pattern. Some cause relatively small changes in drug susceptibility, while combinations can produce substantially greater resistance.
Integrase mutations can change the way antiretroviral medications interact with the integrase enzyme. These structural changes may reduce the ability of medication to block viral DNA integration.
The degree of resistance varies between medications. For example, raltegravir and elvitegravir generally have lower genetic barriers to resistance than second-generation integrase inhibitors such as dolutegravir and bictegravir.
A genetic barrier refers to the number and type of mutations required for HIV to develop clinically significant resistance to a medication. Drugs with higher genetic barriers generally require more complex resistance patterns before their activity is substantially reduced.
Different integrase inhibitors respond differently to specific resistance mutations.
Raltegravir: Resistance may develop through N155H, Q148, or Y143 pathways.
Elvitegravir: Several mutations associated with raltegravir resistance can also affect elvitegravir activity.
Dolutegravir: It generally retains activity against many viruses resistant to first-generation integrase inhibitors, although certain complex mutation combinations can reduce its effectiveness.
Bictegravir: It has a relatively high genetic barrier, but some established integrase resistance patterns may affect its activity.
Cabotegravir: Resistance-associated mutations can reduce susceptibility, particularly when treatment failure occurs in the presence of ongoing viral replication.
The clinical significance of a mutation depends on the complete resistance profile rather than an individual genetic change.
Integrase resistance testing helps identify genetic changes that may affect treatment response. Healthcare professionals may recommend this testing when a person experiences virological failure while receiving an integrase inhibitor-based regimen.
Important aspects of resistance evaluation include:
Genotypic testing: Identifies mutations in the HIV integrase gene associated with medication resistance.
Phenotypic testing: Measures how effectively HIV responds to different antiretroviral medications under laboratory conditions.
Viral load monitoring: Measures the amount of HIV RNA in the blood and helps evaluate treatment response.
Treatment history: Previous medication exposure helps interpret the significance of detected mutations.
Clinical assessment: Healthcare professionals consider resistance results alongside adherence, drug interactions, and other treatment-related factors.
Resistance testing provides important information for understanding why a treatment regimen may no longer suppress viral replication. The findings help clinicians evaluate appropriate treatment options while considering the individual's complete treatment history.